Earlier today Summit Therapeutics announced the results of the PhaseOut DMD clinical trial of Ezutromid.
Although Ezutromid was safe and well tolerated, after 48 weeks the trial clearly showed that there was no clinical benefit for those who received Ezutromid. As a result, Summit have decided to discontinue the development of Ezutromid.
We know this will be really disappointing news to families, but we have to remember that not all trials will be successful. However, we also know that testing a broad range of different approaches can minimise the damage of a failed trial and in Duchenne this is precisely what is happening, and trials of exon skipping, gene therapies and numerous others continue.
“We are naturally disappointed to learn this news, which has come as a shock to our community as a whole. Action Duchenne are here to offer support at this time.”
– Shelley Simmonds, CEO and Duchenne Parent
Summit is now working to bring the on going trials to a close and is working to find a way to make the data from the trial available to the community. This will help researchers working on different potential therapeutic approaches to further advance their work.
Find out more
-
Contact Neil Bennett, Director of Research, to find out more on 020 7250 8240
-
Book ‘early bird’ 2 for 1 tickets for the Action Duchenne Conference
-
More about potential therapies for Duchenne
ReveraGen BioPharma announces preliminary results of Vamorolone trial
